Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ViroLogic, Aclara merging

Infectious diseases and diagnostics company VLGC will merge with ACLA in an effort to form a personalized medicine company focused on cancer and infectious diseases. VLGC will own 52% of

Read the full 309 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE